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Abstract 
Controlled drug delivery systems, which are intended to deliver drugs 
at predetermined rates for predefined periods of time, have been used to 
overcome the shortcomings of conventional drug formulations. 
Injectable drug-loaded matrices and controlled release technology offer 
numerous advantages compared to conventional dosage. However, one of 
the greatest challenges in applying this system to the clinical phase is the 
relatively large initial burst release. 
To reduce this effect of large initial burst release, a new drug delivery 
system was fabricated in this thesis. Both alginate and gelatin are 
biocompatible nature polymers and have been largely used as 
biomaterials for long time. By cross-linking alginate solution carrying 
drug-loaded uncross-linked gelatin microbeads, the initial burst release 
was reduced significantly, compared with drug directly releasing from 
gelatin or cross-linked alginate matrix. 
 
XIV 
 
Firstly, a series of gelatin microbeads were prepared in a water-in-oil 
(W/O) emulsion by a traditional emulsification method. The effects of the 
concentration of gelatin solution, volumetric ratio of water-to-oil phase, 
stirring speed and emulsifying time on the particle size and dispersity of 
gelatin microbeads were studied.  
Secondly, drug-loaded gelatin microbeads were encapsulated into the 
cross-linked sodium alginate macro-beads. The release behavior of drug-
loaded gelatin microbeads encapsulated within cross-linked alginate gel was 
characterized both at room temperature and 37°C and compared with the 
release from gelatin microbeads and cross-linked alginate gel alone. This 
system represents a promise for the development of novel and versatile 
injectable drug delivery systems. 
Thirdly, a dual-drug delivery system was fabricated by encapsulating 
drug-loaded gelatin microbeads into the mixture of cross-linkable sodium 
alginate and another drug. The effects of preparation methods of drug-
loaded gelatin microbeads and ratio between gelatin microbeads and 
alginate on drug release behaviors of both drugs were studied. This system 
shows a significant potential in dual drug delivery field due to the 
synergistic effect between gelatin and alginate. 
Additionally, combination of multi-drugs in one system has been 
revealed as a promising application in the drug delivery systems. 
Therefore, in the fifth chapter of this thesis, an idea for the multi-drug 
delivery system was simply demonstrated. Rods of gelatin gels loaded 
with different drugs were separated by the agarose gel in a polycarbonate 
XV 
 
tube. The effects of the length of agarose gel and temperature on the drug 
release profiles were investigated. The results suggested the feasibility to 
employ this idea to the practical applications. 
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Chapter 1 
Introduction 
 
 
1.1 Drug Delivery Systems 
 
There are some shortcomings in the clinical applications of traditional 
medicines and formulations, such as low effectiveness of the drugs, high 
side effects and the frequent needs of medication to maintain efficacy [1].  
Drug delivery systems (DDS) are the systems to deliver drugs to the 
target sites of pharmacological actions. In detail, DDSs refer to the drug 
carriers, composed primarily of lipids and/or polymers, approaches, 
formulations, technologies, and systems to deliver the drugs in the body as 
needed to safely achieve the required therapeutic effect. Technologies 
employed include those concerning drug preparation, route of 
administration, site targeting, metabolism, and toxicity [2-4]. 
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DDS is designed to efficiently target within the body as the drug 
reservoirs for sustained drug release, to decrease the antigenicity and 
increase the bio-distribution of the loaded drugs, or to reduce the toxicity of 
high drug loading; whatever the case may be, it is mainly concerned with 
dosage form, route of administration and duration of drug presence. Drug 
delivery is often approached via a drug's chemical formulation, but it may 
also involve medical devices or drug-device combination products [5].  
Design, research and production of efﬁcient drug delivery systems are of 
significant importance for the improvement of medicine and healthcare. 
Since the ﬁrst FDA approval of drug delivery system (DDS) in 1990, more 
than 10 DDS are now commercially available to treat diverse diseases 
ranging from cancer to fungal infection and to muscular degeneration 
(Figure. 1.1) [6].  
 
Figure 1.1: Timeline showing FDA approved DDS in the market [6]. 
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With the development of therapeutic efﬁcacy, more and more patients 
have relieved suffering and prolonged life profited from DDS. At the same 
time, drug delivery systems have also changed the economics of drug 
production. As a new product, incorporating an existing drug into a suitable 
drug delivery system not only improves drug’s performance but also reduce 
patents’ suffering and cost. According to the statistics, the average cost and 
time required to develop a new DDS is approximately $20–50 million and 
3–4 years, while it is signiﬁcantly higher to develop a new drug 
(approximately $500 million and over 10 years) [7]. It is not surprising that 
the annual worldwide market for advanced and controlled drug release 
system has grown dramatically [8], especially in the US market [9]. 
Many of the pharmacological properties of conventional drugs can be 
improved through the use of drug delivery systems, Table 1.1 [4] gives 
examples of problems exhibited by free drugs that can be ameliorated by the 
use of DDS. 
With the help of drug delivery systems, drug release profiles could be 
modified, as well as absorption and distribution of the drugs, which improve 
drugs’ efficiency and safety. Moreover, DDS increase patients’ convenience 
and compliance. Most common routes of administration of drugs include the 
preferred non-invasive peroral (through the mouth), topical (skin), 
transmucosal (nasal, buccal/sublingual, vaginal, ocular and rectal) and 
inhalation routes [10]. However, with these common routes, a big problem 
is emerged: many drugs such as peptide, antibody and vaccine cannot be 
delivered and adsorbed into the systemic circulation efficiently and properly. 
The primary reasons come to easily enzymatic degradation, improper 
molecular size and charge-based problems. Therefore, many protein and 
peptide drugs have to be delivered by injection or a nano-needle array. For 
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example, many protein-based insulin and immunizations are often delivered 
by injection. 
Table 1.1 Non-ideal properties and problems of drugs in common routes and 
their therapeutic effects of DDS [4]. 
Problem Implication Effect of DDS 
Poor solubility 
A convenient 
pharmaceutical format is 
difficult to achieve, as 
hydrophobic drugs may 
precipitate in aqueous 
media. Toxicities are 
associated with the use of 
excipients such as 
Cremphor (the solubilizer 
for paclitaxel in Taxol). 
DDS such lipid micelles or 
liposomes provide both 
hydrophilic and 
hydrophobic environments, 
enhancing drug solubility. 
Tissue damage 
on 
extravasation 
Inadvertent extravasation of 
cytotoxic drugs leads to 
tissue damage, e.g., tissue 
necrosis with free 
doxorubicin. 
Regulated drug release 
from the DDS can reduce or 
eliminate tissue damage on 
accidental extravasation. 
Rapid 
breakdown of 
the drug in 
vivo 
Loss of activity of the drug 
follows administration, e.g., 
loss of activity of 
camptothecins at 
physiological Ph. 
DDS protects the drug from 
premature degradation and 
functions as a sustained 
release system. Lower 
doses of drug are required. 
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Unfavorable 
pharmacokinet
ics 
Drug is cleared too rapidly, 
by the kidney, for example, 
requiring high doses or 
continuous infusion. 
DDS can substantially alter 
the PK of the drug and 
reduce clearance. Rapid 
renal clearance of small 
molecules is avoided. 
Poor bio-
distribution 
Drugs that have widespread 
distribution in the body can 
affect normal tissues, 
resulting in dose-limiting 
side effects, such as the 
cardiac toxicity of 
doxorubicin. 
The particulate nature of 
DDS lowers the volume of 
distribution and helps to 
reduce side effects in 
sensitive non-target tissue. 
Lack of 
selectivity for 
target tissues 
Distribution of the drug to 
normal tissues leads to side 
effects that restrict the 
amount of drug that can be 
administered. Low 
concentrations of drugs in 
target tissues will result in 
suboptimal therapeutic 
effects. 
DDS can increase drug 
concentrations in diseased 
tissues such as tumors by 
the EPR effect. Ligand-
mediated targeting of the 
DDS can further improve 
drug specificity. 
 
As shown in Figure 1.2, traditional mechanisms of drug delivery for 
controlling the rate of drug release from polymeric drug delivery systems 
can be summarized as the following four types [11-15]: (1) diffusion-
controlled systems, where the release rate is determined by diffusion 
coefficient of the drug in the current conditions [16], such as PEVAC; (2) 
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swelling-controlled systems, where the release rate of drug is based on the 
water swelling rate of the delivery system, swelling increases the flexibility 
of the polymer and makes larger pores, resulting in better drug mobility [17], 
such as PVA, PHEMA; (3) degradation-controlled systems, where the drug 
release rate depends on the level of chemical or physical degradation of the 
drug delivery matrix, it could be surface degradation or bulk degradation 
[18], such as PLGA, PCL; (4) external stimulus-controlled systems, where 
stimulus-controlled systems release therapeutic factors upon activation by a 
stimulus or multiple stimuli, leading to a physical or chemical change in the 
delivery system, these stimuli could be physical (e.g., pH, temperature) or 
chemical (e.g., the presence of glucose) [5], such as PNIPAM, PDMAEMA.  
 
 Figure 1.2 : Summary of four traditional mechanisms of drug delivery 
systems: diffusion-controlled, swelling-controlled, degradation-controlled, 
and stimuli-controlled systems [11]. 
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Among the four common mechanisms, initial drug burst was inevitable. 
The novel concept of using chemical affinity in drug delivery systems can 
reduce initial burst and control drug release availably. As defined, affinity is 
the tendency of a molecule to associate with another molecule. It may come 
from many chemical or physical interactions, such as covalent bond, 
charged interaction, hydrogen bonding or van der Waals forces. It has been 
reported that stable polyion complex can be formed by the electrostatical 
interaction between two polyelectrolytes with opposite charges. By the 
interaction or affinity between drug and polymeric matrices, drug loading 
and release could be controlled [11, 19]. 
Recently drug delivery system includes oral drug delivery system, trans-
dermal drug delivery system, mucosal drug delivery system, targeted drug 
delivery system, cell micro-encapsulated drug delivery system and micro-
fabricated drug delivery system. 
The main efforts in the field of drug delivery include the development of 
targeted delivery and sustained release formulations. To be specific, the 
drug would be only active in the target area of the body (for example, in 
cancerous tissues) in the targeted DDS and the drug would be released over 
a period of time in a controlled manner in the sustained DDS. In order to 
realize the efficiency of targeted delivery, the designed system must avoid 
the body's immune mechanisms and then manage to deliver the drugs to its 
intended site of action. Types of sustained release formulations include 
liposomes, drug loaded biodegradable microspheres and drug polymer 
conjugates. 
Innovation and development in materials have initially driven the 
progress of DDS. Various kinds of carriers have been created, like 
biodegradable, biocompatible, targeting, stimulus-responsive and injectable 
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materials. Nanotechnology has also contributed much to the development of 
DDS in the past decade. Since then when it was found that size and shape of 
nanoparticles (NPs) could help navigate biological carriers,  the application 
of nanofabrication technologies has motivated to develop more effective 
particulate DDS, both top–down and bottom–up. As reported, the size of 
NPs regulates their bio-distribution. Particles less than 20 nm will be cleared 
from circulation via reticuloendothelial system (RES) within a few hours 
when injected intravenously, whereas larger ones will be trapped in the liver 
and the spleen within minutes [20, 21]. In a study of Kataoka and his 
colleagues, the results showed that polymeric micelles only less than 30 nm 
could effectively penetrate poorly permeable pancreatic tumor cells [22]. 
Fabricating techniques such as nano-precipitation, emulsion-based phase 
inversion, microﬂuidics-based self-assembly, layer-by-layer synthesis, and 
nano-imprinting have been used to generate particulate DDS to deliver a 
wide range of drugs. With the full understanding of the potential of 
particulate DDS in required size and shape, nano-fabrication and nano-
manufacturing will play a more and more prominent role in the future. 
As the carriers of drug delivery systems, they could be these traditional 
biodegradable polymers, such as poly (lactic acid) (PLA), poly (glycol acid) 
(PGA) and their copolymers, poly (lactide-co-glycolide) (PLGA), they are 
the most widely used for the development of drug delivery system because 
of their biodegradability, biocompatibility and ease of processing [23, 24]; 
they could be  block copolymers, such as poly (propylene oxide)-poly 
(ethylene oxide)- poly(propylene oxide) (PPO-PEO-PPO) (Pluronic) 
triblock copolymer, developed by Kabanov et al., they have attracted the 
thoughts of researchers since the early days of drug delivery because of their 
remarkable chemical flexibility. Depending on the choice of building blocks, 
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they could assemble to nanostructures in the form of micelles, electrostatic 
complexes, or polymersomes [25]; they could be polymer drug conjugates, 
conjugation to a polymeric carrier via a liable linker presents another 
attractive approach to alter and optimize the pharmacokinetics of 
therapeutic agents [6]; they could be natural polymers derived from 
biological systems including protein, DNA, and polysaccharides, they are 
biocompatible and biodegradable, moreover, they possess low toxicity and 
potentially favorable pharmacokinetics in the circulation [6]; they also could 
be recombinant protein-based drug carriers. 
 
1.2 Gelatin 
 
Nowadays, gelatin is utilized in practically all areas of modern life. 
However, interest in gelatin is not just restricted to classical applications; 
this natural product has numerous other application possibilities. New 
applications in health care and in specialized technical areas will result in 
gelatin and gelatin hydrolysates becoming a focal point of concern for a 
much wider pubic [26].  
The first known gelatin by boiling animal tissues to use as glue should 
date back to about 8000 years ago. The revolution in the use of gelatin for 
biomedical applications occurred in 1833 when gelatin capsules were first 
fabricated to encapsulate drugs to prevent drugs from heat, humidity and to 
make drugs taste no longer bitter. In the 20
th
 century, the application of 
gelatin in medical field exploded [26].   
Gelatin is a mixture of protein, which is easily available through native 
collagen hydrolysis processing of animal skin (it would be possible to use 
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also bones, but it is more difficult; for economical and practical reasons, skin 
is usually preferred), either by partial acid or alkaline hydrolysis at a 
moderate temperature; the content of protein ranges from 85% to 92%, the 
remnant consists of salts and moisture remained after drying [26-28]. 
By controlling type and intensity of the hydrolysis, it is possible to 
control the molecular weight distribution. Gelatin hydrolyzed with alkaline 
treatment (type B) shows a narrower distribution, while type A gelatin has a 
broader distribution. Molecular weight will affect viscosity and gelling 
power. Both of them are increased by the increase in the molecular weight. 
The gel strength is the most important quality parameter for gelatin. The 
analytical measure of gelling power is the Bloom value, which is the weight 
required for a specified plunger to depress the surface of a standard, 
thermostatted gel to a defined depth under standard conditions. 
Gelatin undergoes a sol-gel phase transition at a temperature close to 
35°C, which can slightly vary due to gel strength, concentration and thermal 
history of the material [26, 29]. The kinetics of gel formation of gelatin can 
be explained by the formation of intermolecular hydrogen bonds (Figure 1.3). 
When gelatin solution is cooled down, the mobile molecules aggregate to 
small clusters; these continuously grow and subsequently form the gel [26]. 
Usually the gelation temperature of gelatin is 5 °C below the melting 
temperature. The unique ability to react with heat (undergo gel-to-sol 
transition at body temperature) has made animal-derived gelatin extensively 
used as gelling agents in the modern food, biomaterial, medical and 
pharmaceutical industry [1, 26, 30-33]. However, uncross-linked gelatin 
hydrogels tend to be in liquid phase at body temperature and this is usually a 
limiting factor for in vivo applications. Therefore, chemically cross-linked 
gelatin has been used as a substitution widely for tissue engineered scaffold 
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and as carrier for drugs, gene therapeutic entities and cells [32, 34-38], 
although it is non-degradable and loses the ability for the sol-gel transition in 
vivo. 
 
Figure 1.3: Model of gel formation (from sol to gel upon cooling) [26] 
 
Drug delivery systems based on this polymer are known to be 
biocompatible, biodegradable without toxic by-products and characterized 
by low immugenicity. Gelatin is a polyampholyte having both cationic and 
anionic groups along with hydrophilic groups. The electrical nature of 
gelatin, which can be changed by the hydrolysis processing method--acid 
treatment for basic gelatin; alkaline treatment for acid gelatin, has endowed 
it another unique advantage as a drug carrier [1, 31-33]. Thanks to the 
duplicity of gelatin, different type of gelatin (type A: basic; type B: acidic) 
would be chosen[39, 40] to meet the demand of immediate [41] or sustained 
[31, 40] drug release, depending on the alkalinity or acidity of drug and 
application. Furthermore, conjugates formed by gelatin and drug have many 
advantages, including biodegradability, low antigenicity with the potential to 
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overcome immune problems and reducing the toxicity of high drug loading 
[42, 43]. 
 
1.3 Alginate 
 
Commercial alginates are mainly extracted from three kinds of native 
brown seaweed: Laminaria hyperborean, Ascophyllum nodosum, and 
Macrocystis pyrifera [44]. Alginate, the primary polysaccharide in the these 
seaweed, is found in the intracellular matrix. The native alginate is mainly 
present as an insoluble Ca
2+
 cross-linked gel [45].  
Figure 1.4: Structure of alginate [46] 
 
Alginate is a family of linear unbranched polysaccharides which contain 
varying amounts of 1, 4’-linked β-D-mannuronic acid (M) and α-L-
guluronic acid (G) residues, as shown in Figure 1.4 [46]. Cross-linking of 
alginate gel can take place easily in mild conditions when the solution of 
sodium alginate meets divalent cations, such as Ca
2+
, Ba
2+
 or Sr
2+
, these 
cations cooperatively interact with blocks of G monomers forming ionic 
inter-chain bridges (characteristic egg-box structure) and causing the 
gelification of the alginate solution [47-49], the schematic representation is 
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shown in Figure 1.5. Among these cations, Ba
2+
 or Sr
2+
 ions produce 
stronger alginate gels than Ca
2+
 [49-51]. However, monovalent cations and 
Mg
2+
 ions do not induce gelation, other divalent cations also can cross-link 
alginate but their use is limited due to the toxicity.  
 
Figure 1.5: Schematic representations of the poly-L-guluronate sequences of 
alginate cross-linked by calcium ions [49]. 
 
Alginate has been widely used in food and beverage industries as well as 
tablet manufacture for long time [52]. Due to the large availability in nature, 
the mildness of gelation conditions, limited toxicity, great biocompatibility, 
low immunogenicity, and low cost [47, 49, 52, 53], alginate has been widely 
proposed as a potential biopolymer for drug stabilization, tissue engineering, 
and controlled-release systems, as well as for cells encapsulation techniques 
[54-58].  
Recently alginate gains increasing interests in its applications as scaffolds 
of injectable, self-cross-linkable and long-term degradable hydrogels. 
Development on injectable auto-forming alginate gel by encapsulating 
calcium phosphate or calcium-rich alginate microbeads into alginate solution 
as well as blending oxidized alginate with gelatin solution has been 
reported[13, 41, 59-61]. Alginate solutions also have been shown to form 
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gels in situ when placed on the surface of the eye [62]. Ito et al.[61] reported 
that cross-linking of alginate could occur spontaneously once injected into a 
living body because of divalent cations in the organism. In addition, 
although cross-linked alginate is non-biodegradable, degradation can occur 
by removal of the cross-linking ions[49], for instance, alginate gels will 
degrade in 0.1 M phosphate buffer solution[63]. Therefore, since the exit of 
HCO3
-
 and HPO4
2-
 in the human body fluid[61], the degradation of alginate 
gels can also take place in vivo. However, majority of them suffer the 
problem on fast release of encapsulated drugs which limits its application as 
the matrix of drug delivery system. To prolong the duration of drug release, 
it is a feasible way to immobilize drugs to charged polymer carriers by 
electrostatically interaction to form a polyion complex [64] or embed drug-
loaded microbeads in polymeric matrix. Varied microbeads, micelle and 
beads were developed to trap drugs and delivery the drugs with assistance of 
polymeric matrix [65-69], and for the polyion complexation for sustained 
release, it is necessarily bio-safe and biodegradable.  
 
1.4 Objectives 
 
The aim of this research is to develop an uncross-linked gelatin based 
composite to be used for drug delivery system or multi-drug delivery system. 
The composite should have the ability to control the rate of drug release as 
needed, no matter immediate release or sustained release. It also should 
have the following characteristic: non-toxicity, great biocompatibility, low 
immunogenicity, low cost and degradability in vivo. The scheme of my 
study was shown in Figure 1.6. 
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Figure 1.6: The scheme of the thesis. 
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Chapter 2   
Preparation and characterization of 
gelatin microbeads 
2.1    Introduction 
In recent years the application of encapsulating micro-particles into drug 
delivery system has gained more and more attentions. Due to different kinds 
of drug needs, such as immediate release, sustained release of constant drug 
concentration for some time or targeting to specific cells or organs, drug 
delivery systems based on the particles have widely utilized in experimental 
therapeutics. For instance, antineoplastic drugs have been selectively 
targeted with antitumor agents to obtain higher drug concentration at the 
tumor site in real clinical application [70, 71] . As for the sustained release, 
the direct relationship between route of administration and particle size 
should be considered.  
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Microspheres with diameter in the range of 20-100 μm can be chosen for 
subcutaneous or intramuscular administration as sustained release depots. 
Smaller micro-particles have been considered for the treatment of infection 
and arthritis [72]. 
Embedding biodegradable particles into the formulation turns to be 
efficient to improve the therapeutic effect of various water soluble/insoluble 
medicinal drugs and bioactive molecules. In this way, absorption, 
bioavailability, intracellular penetration, solubility and retention time of 
drugs in the selected tissue are improved. The resulting formulation would 
reduce the risks of side effect and the cost of patients and protect the 
premature degradation and interaction with the biological environment [73-
76]. 
Drugs or bioactive molecules related to some dreadful diseases like 
cancer, AIDS, diabetes, malaria and prion disease are successfully 
encapsulated into nano- or micro-particles to improve bioavailability, 
bioactivity and control delivery, some of them are already commercialized 
[77-81].  
The size of the particles plays a significant role in the aspect of properties 
of the final product as well as potential applications during the drug release. 
Size also has a marked effect on particle distribution throughout the body. 
When delivered in vivo, large particles will tend to lodge in the injected 
tissues or small vessels [82], while smaller ones, especially  nanoparticles, 
may circulate in the bloodstream or may be eliminated by white blood cells 
for a period of time determined by many elements, such as size and surface 
chemistry [83]. As for the ability to overcome the biological obstacles, 
nanoparticles can easily achieve this; while, for the microparticles, the only 
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two ways to cross the most barriers are injection and carrying by a particular 
cell type. 
In this chapter, gelatin microbeads would be prepared under all kinds of 
conditions by emulsification and the optimal parameter would be selected to 
obtain the suitable drug-loaded gelatin microbeads. 
 
2.2    Materials  
 
Gelatin (gelatin type A, gel strength ~300 g Bloom, from porcine skin), 
soybean oil, nonionic surfactant sorbitane monooleate (Span
®
 80) and n-
Hexane were purchased from Sigma-Aldrich (Milan, Italy). All the 
materials were used as received without further puriﬁcation. 
2.3    Methods 
2.3.1 Preparation of gelatin solution 
Different gelatin aqueous solutions were prepared by soaking gelatin 
powder in deionized water for 10 minutes, at room temperature, to allow 
gelatin swelling by absorbing a certain amount of liquid. The suspensions 
were then placed in a 40 °C bath for one hour and stirred every 20 minutes 
by using a vortex mixer until a clear gelatin solution was obtained.  
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2.3.2 Preparation of oily phase 
Oily phase was a mixture of commercial soybean oil and Span
®
 80, 
prepared in a proportion of 20 mg of Span
®
 80 per 1 mL of soybean oil 
under mild stirring in a 40 °C water bath. 
2.3.3 Preparation of gelatin microbeads 
An emulsification-coacervation method was employed to prepare gelatin 
microbeads [84-87]. Briefly, a gelatin solution prepared as in section 2.3.1 
was added dropwise into the oily phase prepared as in section 2.3.2 under 
continuous stirring in a 40 °C water bath to obtain a water-in-oil (W/O) 
emulsion. Different volume ratio between gelatin solution and oily phase 
was used. The effects of emulsifying time ranging from 2 to 15 min and 
stirring speed ranging from 200 to 1000 rpm on the W/O emulsion were 
also considered. After this stage, the emulsion was moved to an ice-bath and 
stirred for other 30 min at 200 rpm to complete the gelation of the gelatin 
microbeads inside the continuous oily phase. Oil was then removed with 
several washings in n-hexane and gelatin microbeads were placed in a 
vacuum drier overnight to remove hexane.  
2.3.4 Characterization of gelatin microbeads 
Gelatin microbeads obtained in the different conditions were imaged with 
optical microscope (Axiotech, Carl Zeiss, Germany). For particle size, at 
least 30 microbeads per image were measured and analyzed using ImageJ 
software (National Institutes of Health, Bethesda, MD, USA). All the data 
were presented as mean ±  standard deviation. Statistical analysis was 
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performed using OriginPro software (OriginLab, Northampton, MA, USA) 
with significance level of p < 0.05. 
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2.4    Results and Discussion 
2.4.1 Characterization of gelatin microbeads 
Emulsification method has been widely applied to the preparation of 
micrometric beads for its outstanding advantages such as easy-controlling 
and mild-condition operation, which was first proposed by Tanaka.[88] In 
this study a plant-derived soybean oil was chosen as the oily phase for 
safety considerations because it is often difficult to completely remove the 
oil after microbeads preparation.[89]  
Solid and water stable gelatin microbeads with homogenous size and 
spherical shape and narrow distribution were prepared by water-in-oil (W/O) 
emulsification method. The particle size of gelatin microbeads was strongly 
dependent on the different operational parameters used during preparation. 
In the present study, the influence of gelatin concentration, emulsifying 
speed, the ratio between gelatin solution and oily phase, and emulsifying 
time on particle size were investigated. 
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2.4.1.1 Effect of the concentration of gelatin solution on 
the size of gelatin microbeads 
 
Figure 2.1 Average diameter of gelatin microbeads prepared from gelatin 
solution of different concentrations (ratio between water phase and oily 
phase: 1:5, stirring speed: 800 rpm and emulsifying time: 10 minutes)  
 
The concentration of gelatin solution is one of the important parameters 
that influence the morphology and size of gelatin microbeads. When the 
concentration of gelatin solution is lower than 20 μg/mL, it is difficult for 
the gelatin solution to form the microbeads. For the water content in the 
drop of gelatin solution is too high, once the drop cools down to form the 
gel, the shape of particles obtained will be irregular after dehydration and 
the inner structure of the particles will be very loose. Therefore, it is not 
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proper to prepare gelatin microbeads by using low concentration gelatin 
solution. 
In our case, five concentrations of 50 μg/mL, 75 μg/mL, 100 μg/mL, 125 
μg/mL and 150 μg/mL (5%, 7.5%, 10%, 12.5%, 15% (w/v)) were chosen to 
obtain different gelatin microbeads for comparison by fixing the ratio of 1: 5 
between gelatin solution and oily phase, stirring speed of 800 rpm and 10 
min of emulsifying time. 
As shown in Figure 2.1, the particle size of gelatin microbeads increased 
almost linearly from 6.8 ± 0.9 m to 30.6 ± 1.8 m with the concentration 
of gelatin solution ranging from 5% to 15%. 
From Figure 2.2, it could be seen that when gelatin microbeads were 
prepared from low-concentration gelatin solution, the microbeads with 
smaller particle size had a strong tendency to agglomerate, which attributed 
to the high water content in the gelatin microbeads. During the stirring of 
preparation, it was easy to destroy the inner loose structure of gelatin 
microbeads, which would lead to the particles stick to each other.  
With the increase of concentration of gelatin solution, the morphology 
and the dispersity of the gelatin microbeads would be improved 
significantly, the phenomenon of agglomeration would disappear, as shown 
from Figure 2.3. 
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Figure 2.2. Optical image of gelatin microbeads in oily phase prepared from 
50 μg/mL gelatin solution (ratio between water phase and oily phase: 1:5, 
stirring speed: 800 rpm and emulsifying time: 10 minutes) 
 
Figure 2.3 Optical image of gelatin microbeads in oily phase prepared from 
75 μg/mL gelatin solution (ratio between water phase and oily phase: 1:5, 
stirring speed: 1000 rpm and emulsifying time: 10 minutes) 
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2.4.1.2 Effect of stirring speed on the characterization of 
gelatin microbeads 
 
Figure 2.4 Average diameter of gelatin microbeads prepared at different 
gelatin concentrations (ratio between water phase and oily phase: 1:5, 
stirring speed: 800 rpm and emulsifying time: 10 minutes)  
During the emulsification, five stirring speed of 200 rpm, 400 rpm, 600 
rpm, 800 rpm and 1000 rpm were chosen to obtain different gelatin 
microbeads for comparison by fixing the ratio of 1: 5 between gelatin 
solution and oily phase, the concentration of gelatin solution of 100  μg/mL 
(10%) and 10 min of emulsifying time. 
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Figure 2.5 Optical image of gelatin microbeads in oily phase prepared from 
150 μg/mL gelatin solution (ratio between water phase and oily phase: 1:5, 
stirring speed: 400 rpm and emulsifying time: 10 minutes) 
 
As shown in Figure 2.4, particle size of gelatin microbeads resulted 
inversely proportional to stirring speed in the tested range. Water and oil 
phase were typically mixed in a 10 mL beaker with a 12 mm magnetic 
stirring bar. Under these conditions, low stirring speed of 200 rpm produced 
microbeads with a diameter of 39.3 ± 1.9 µm; nevertheless, high speed of 
1000 rpm resulted in a much smaller diameter (7.8±1.6 µm). In addition, 
when the stirring speed is lower than 400 rpm, the distribution of the 
particle size is rather wide; there are a lot of small gelatin microbeads 
sticking to the big gelatin microbeads; while when the stirring speed is 
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higher than 1200 rpm, the phenomenon of agglomeration would become 
more and more serious. It could be explained that when agitation was 
carried out at lower speed, the water phase couldn’t be dispersed into 
droplets efficiently with insufficient shearing force and the emulsion formed 
is not stable. Meanwhile, the gelatin microbeads tended to aggregate 
together to form the flocculation. Therefore, the size of microbeads obtained 
distributed in a wide range. However, with the gradual increase of stirring 
speed, the shearing force at each point of the emulsion increased 
progressively and became uniform, which led to the decreased diameter and 
narrower size distribution of gelatin microbeads. When the stirring rate 
continued increasing to a critical point, turbulence would form in the 
emulsion system, which brought uneven physical acting force on droplets. 
The occurrence of deformation and breakage due to the collision of droplets 
would increase dramatically, which resulted in the destruction of spherical-
shaped microbeads and further inhomogeneity in size distribution[70, 90].  
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Figure 2.6 Optical image of gelatin microbeads in oily phase prepared from 
100 μg/mL gelatin solution (ratio between water phase and oily phase: 1:5, 
stirring speed: 800 rpm and emulsifying time: 10 minutes) 
 
Representative optical images of microbeads obtained under different 
conditions were presented. Large-sized microbeads (50.5 ± 16.4 µm) 
prepared at low speed of 400 rpm and from high-concentration gelatin 
solution of 150 μg/mL (15%) are shown in Figure 2.5; medium-sized 
microbeads (13.9±2.8 µm) prepared at medium speed of 800 rpm and 
medium concentration of 100  μg/mL (10%) are shown in Figure 2.6; small-
sized microbeads (6.7 ± 1.8 µm) prepared at high speed of 1000 rpm and 
low concentration of 75 μg/mL (7.5%) are shown in Figure 2.3. Other 
conditions of all the images were the same: ratio between water phase and 
oily phase: 1:5 and emulsifying time of 10 minutes. The homogeneity of 
particle size declined with the increase of diameter. 
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Figure 2.7 Optical image of treated gelatin microbeads prepared from 100 
μg/mL gelatin solution (ratio between water phase and oily phase: 1:5, 
stirring speed: 800 rpm and emulsifying time: 10 minutes) 
 
After several washings with n-hexane and then putting in a vacuum drier 
for one hour, the optical image of treated medium-sized gelatin microbeads 
was taken and presented in Figure 2.7. These microbeads are small, round 
and opaque. 
After putting the treated gelatin microbeads into deionized water again, 
these gelatin microbeads started to absorb water and then became bigger 
and bigger, at last changed from opaque to transparent. The optical image 
was shown in Figure 2.8. They tended to stick to each other; however, it 
was very easy to make them uniform when under stirring. The big black dot 
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in the image was the residue of oil or n-hexane around the treated gelatin 
microbeads. 
 
 
Figure 2.8 Optical image of treated gelatin microbeads after putting in 
deionized water prepared from 100 μg/mL gelatin solution (ratio between 
water phase and oily phase: 1:5, stirring speed: 800 rpm and emulsifying 
time: 10 minutes) 
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2.4.1.3 Effect of the ratio between gelatin solution and 
oily phase on the characterization of gelatin microbeads 
 
Figure 2.9 Average diameter of gelatin microbeads prepared at different 
ratio between gelatin solution and oily phase (concentration of gelatin 
solution: 100 μg/mL (10%), stirring speed: 800 rpm and emulsifying time: 
10 minutes)  
 
    Besides the concentration of gelatin solution and stirring speed, another 
important parameter in the emulsion system is the ratio between water phase 
and oily phase, which had great influence on the morphology of gelatin 
microbeads. 
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    The same as above, fixing other parameters, such as 100 μg/mL (10%) of 
the concentration of gelatin solution, 10 min of emulsifying time, 800 rpm 
of stirring speed, three different volume ratio between water phase and oily 
phase of 1:8, 1:5 and 1:3 were chosen to obtain different gelatin microbeads 
for comparison. 
   As shown in Figure 2.9, with the increase of water phase from 1:8 to 1:3, 
the particle size of gelatin microbeads increased from 10.9 ± 1.1 m to 24.8 
± 1.4 m. Based on the results, it could be concluded that decreasing the 
ratio between water phase and oily phase, the ability of oily phase to 
disperse the gelatin solution would be increased, which would lead to the 
formation of small gelatin microbeads. 
2.4.1.4 Effect of emulsifying time on the characterization 
of gelatin microbeads 
It takes some time for the dispersed phase to form the stable emulsion 
droplets under the external physical force. Therefore, to obtain the stable 
gelatin microbeads of good morphology and dispersity, the effective control 
of emulsifying time must be considered. Although emulsifying time had 
little influence on the particle size, it affected size dispersity and sphericity 
of gelatin microbeads, emulsifying time between 5 and 15 min made gelatin 
microbeads more homogenous and smoother. Emulsifying time less than 5 
min or more than 15 min would result in the wide distribution of particle 
size and agglomeration of the gelatin microbeads, as shown in Figure 2.10 
and Figure 2.11. 
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Figure 2.10 Optical image of gelatin microbeads in oily phase prepared 
under the following conditions: 100 μg/mL gelatin solution, volume ratio 
between water phase and oily phase: 1:5, stirring speed: 800 rpm and 
emulsifying time: 3 minutes. 
 
Figure 2.11 Optical image of gelatin microbeads in oily phase prepared 
under the following conditions: 75 μg/mL gelatin solution, volume ratio 
between water phase and oily phase: 1:5, stirring speed: 1000 rpm and 
emulsifying time: 18 minutes. 
34 
 
2.5    Conclusions 
A series of gelatin microbeads were prepared through emulsification-
coacervation method in water-in-oil (w/o) emulsion. The influence of 
preparation parameters on particle size, surface morphology and dispersity 
of gelatin microbeads was examined. The studied parameters include 
concentration of gelatin solutions, water phase/ oil phase ratio, emulsifying 
time and stirring speed. The experimental results indicated that increasing 
the concentration of gelatin solution would increase the particle size of 
gelatin microbeads linearly. The water/oil ratio had the same influence on 
the particle size as that of gelatin solution concentration. In addition, with 
the increase of water/oil ratio, the surface of microspheres became smoother 
as well. The emulsifying time had little effect on the mean diameter of 
gelatin microbeads, but it affected the dispersity of particles apparently. 
When emulsifying time was shorter than 5 min or longer than 15 min, 
gelatin microbeads had bad dispersity. The stirring speed had the similar 
influence as that of emulsifying time. Slow stirring rate made large size 
distribution and bad sphericity; excessive stirring speed resulted in 
aggregation likewise. The smaller size distribution and better sphericity of 
gelatin microbeads were observed under the stirring speed between 500 rpm 
to 1200 rpm.  
In conclusion, increasing the concentration of gelatin solution or w/o 
ratio would increase the particle sizes of gelatin microbeads, proper 
emulsifying time and stirring speed would result in the narrow size 
distribution and best sphericity of gelatin microbeads. The excellent result 
was obtained with the condition: 100 μg/mL (10%) gelatin solutions, 1: 5 of 
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water/oil volume ratio, 10 min of emulsifying time and 800 rpm of the 
stirring speed. 
 
36 
 
Chapter 3 
Drug delivery system of gelatin 
microbeads embedded in alginate 
3.1    Introduction 
The development of injectable drug-delivery systems has gained 
extensive attention over the last decade [91]. These systems possess unique 
advantages when compared to traditional administration routes, including 
localized and tissue-specific delivery, programmable release patterns, 
efficient loading and delivery, reduction of undesired side effects and 
minimally invasive administration [92, 93]. 
Recently, there has been growing interest in injectable hydrogels which 
can undergo solution-to-gel (sol-gel) transition in situ after injection in 
response to chemical or physical stimuli [94, 95].  
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A wide range of synthetic and natural polymer-based materials have been 
proposed to form injectable hydrogels for drug delivery and cell 
encapsulation. Back to 1997, Jeong et al. synthesized a thermosensitive and 
biodegradable injectable hydrogel consisting of PEO and PLLA blocks as 
drug delivery systems [96]; since then, a variety of block copolymers of 
Poly(ethylene glycol) and degradable, biocompatible aliphatic polyesters 
with tailored degradation behavior and hydrophobicity were proposed as 
hydrogel-based drug carriers [97-99]. However, it is generally complicated 
to standardize the synthesis of these custom-made block copolymers; in 
addition, their synthesis methods often involve toxic solvents and reagents 
that are difficult and expensive to remove, instability of the functional 
groups and low coupling efficiency.  
Naturally-derived polymers have been largely used as hydrogels for drug 
delivery due to inherent bio-compatibility, bio-resorbability, bio-adhesive 
properties, and the resemblance to natural extra cellular matrix. Hydrogel-
forming biopolymers include collagen and cross-linked gelatin, chitosan, 
agarose, fibrin and alginate [34, 100-103].  
Injectable drug-loaded matrices and controlled release technology offer 
numerous advantages over conventional dosages. Cross-linkable alginate 
hydrogels have been proposed for in vivo injection, but their large initial 
burst release of encapsulated drugs represents a limitation for the transition 
to the clinical phase. To reduce this effect, a newly designed, cost effective, 
ease to prepare and very versatile drug delivery system for the encapsulation, 
delivery and release of hydrophilic molecules was demonstrated by 
combining uncross-linked, drug-loaded gelatin microbeads with cross-
linkable alginate solution to generate a composite drug delivering hydrogel 
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in this chapter, the schematic representations of process was shown in 
Figure 3.1.  
Hydrophilic fluorescein (FL) was chosen because it is a widely used 
model drug agent comparable with many chemotherapeutic drugs [104]. 
The release profile of FL from composite hydrogels was studied and 
compared with release profiles from the single constituents. In the 
gelatin/alginate composite hydrogel, the synergistic interplay between the 
two components overcomes the limitations of both alginate and gelatin gels. 
Gelatin offers a great flexibility in terms of available formulations and 
variety of drugs that can be incorporated. As shown in the chapter, gelatin 
microbeads help suppressing burst release and greatly extend the time span 
for sustained release when compared to alginate gel. On the other side, 
cross-linkable alginate is a very stable and practical carrier for gelatin 
microbeads and prevents gelatin from being immediately disperse upon 
melting after insertion in vivo. This new gelatin/alginate composite 
hydrogel shows a potential for the sustained release of hydrophilic 
molecules and the design of more versatile alginate-based injectable drug 
delivery systems. 
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Figure 3.1 Schematic representations of the preparation of gelatin 
microbeads (Gm), encapsulation in cross-linkable alginate matrices and 
drug release analyses. A: preparation of liquid Gm loaded with FL by W/O 
emulsification in oil bath; B: cooling in ice-bath for complete gelation of 
Gm; C: extraction of solid Gm by hexane washing and release analysis; D: 
cross-linking of alginate gels encapsulated with solid Gm in CaCl2 solution; 
E: drug release experiments from composite gels at RT (solid Gm) and 
37°C (liquid Gm). 
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3.2    Materials 
 
Gelatin (gelatin type A, gel strength ~ 300 g Bloom, from porcine skin), 
Sodium Alginate (Alginic acid sodium salt from brown algae), Fluorescein 
(FL), Calcium Chloride, soybean oil, nonionic surfactant sorbitane 
monooleate (Span
®
 80) and n-Hexane were purchased from Sigma-Aldrich 
(Milan, Italy). All the materials were used as received without further 
puriﬁcation. 
3.3    Methods 
3.3.1 Preparation of FL-loaded gelatin microbeads 
FL-loaded gelatin microbeads were prepared with a similar process as 
described in section 2.3.3 under the optimal emulsification condition: 100 
μg/mL (10%) gelatin solution, 1: 5 of water/oil volume ratio, 10 min of 
emulsifying time and 800 rpm of the stirring speed, where fluorescent 
molecules were mixed directly into the gelatin aqueous solution prior to the 
emulsification. Different gelatin solutions were prepared with FL 
concentrations equal to 5, 20 and 40 µg/mL.  
3.3.2 Confocal images of FL-loaded gelatin 
microbeads 
Confocal images of FL-loaded gelatin microbeads were taken with the 
laser confocal microscope (Nikon A1, Tokyo, Japan). 
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3.3.3 Preparation of FL-loaded gelatin and in vitro 
drug release from FL-loaded gelatin/gelatin 
microbeads 
A gelatin aqueous solution at a concentration of 10% (w/v) was prepared 
by dissolving gelatin powder in deionized (DI) water at 40°C for 30 min. 
Fluorescein (FL) was mixed into the solution to obtain a concentration of 20 
µg/mL. 3 mL of the solution was filled into a 10-mm dialysis tubes 
(Regenerated cellulose dialysis membrane, MWCO 3500, Spectra/Por
®
, 
Spectrum Lab., CA, USA) and natural gelation was allowed at RT. Each 
dialysis tube was placed into a beaker with 60 mL of DI water under mild 
agitation to test the release of FL in time. The release experiment was 
performed both at room temperature (23 ± 1°C) and at body temperature (37 
± 1°C); three samples were tested for each experimental condition. For 
comparison, gelatin microbeads obtained from 10% (w/v) gelatin solution 
with 20 µg/mL of FL were also tested for the release in the same conditions. 
Every hour 1 mL of surnatant was extracted from each sample to determine 
the FL content, and replaced with fresh DI water. All the extracted samples 
were stored at 4°C in dark until all the time points were collected. 
3.3.4 Preparation of FL-loaded cross-linked alginate 
gels 
A 1% (w/v) alginate aqueous solution was prepared by dissolving 
alginate powder in DI water at RT under mild agitation for 2 hours and then 
moved to an ice bath. Here, previously prepared FL-loaded gelatin 
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microbeads were uniformly dispersed into the alginate solution by 
continuous stirring for 5 min as shown in Figure 3.1(d). The stirring was 
completed in the ice bath to avoid too much FL releasing from gelatin 
microbeads. Volumetric ratio of 3 to 1 for alginate solution to gelatin 
solution was used to prepare the samples. After stirring, the alginate 
solution with dispersed gelatin microbeads was immediately injected 
dropwise into a 3% (w/v) CaCl2 aqueous solution to induce alginate cross-
linking and to form macroscopic alginate beads carrying FL-loaded gelatin 
microbeads.  
 
Table 3.1 Tested samples 
Sample code Description 
Gm Gelatin microbeads 
Gb Gelatin directly loaded with fluorescein in bulk 
Alg-1.25 Alginate macrobeads loaded with 1.25 g/mL 
fluorescein 
Alg-5 Alginate macrobeads loaded with 5 g/mL fluorescein 
Alg-10 Alginate macrobeads loaded with 10 g/mL fluorescein 
Alg(Gm-5) Alginate macrobeads encapsuled with Gelatin 
microbeads containing 5 g/mL fluorescein 
Alg(Gm-20) Alginate macrobeads encapsuled with Gelatin 
microbeads containing 20 g/mL fluorescein 
Alg(Gm-40) Alginate macrobeads encapsuled with gelatin microbeads 
containing 40 g/mL fluorescein 
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With this process, gelatin microbeads prepared from different FL 
concentrations (5, 20 and 40 µg/mL) were incorporated in alginate; the 
obtained composite gels are hereinafter named Alg(Gm-5), Alg(Gm-10), 
and Alg(Gm-20). For comparison, alginate macrobeads directly loaded with 
FL were also prepared. In this case, alginate was dissolved in aqueous 
solutions of FL at concentrations of 1.25, 5 and 10 µg/mL. FL-loaded 
alginate macrobeads with different content of FL were produced 
(hereinafter Alg-1.25, Alg-5 and Alg-10). These FL concentrations were 
specifically calculated to obtain the same absolute content of FL present in 
the previously described Alg(Gm-5), Alg(Gm-10), and Alg(Gm-20) 
samples. All the samples and compositions were summarized in Table 3.1. 
3.3.5 In vitro drug release from FL-loaded cross-
linked alginate gels 
Release studies of FL-loaded gelatin/alginate composite gels were 
conducted by adding 2 mL of deionized water to a vial containing alginate 
macrobeads, as presented in Figure 3.1(e). 1 mL supernatant of each sample 
was collected at predetermined time intervals for fluorescence intensity test 
and the same amount of deionized water was added. The collected samples 
were stored at 4°C in dark until all the time points were collected. Drug 
distribution in the composite hydrogels was monitored by confocal 
microscopy before and during the release experiment. After 7 days of 
release, Alg(Gm-5), Alg(Gm-10), and Alg(Gm-20) composite hydrogels 
were immersed in PBS at 37°C for 24 hours to re-dissolve cross-linked 
alginate and free unreleased FL and gelatin. After centrifugation, 
supernatant was collected and analyzed to measure FL content. 
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3.3.6 Calibration curve of FL in DI water 
The stock solution of FL was prepared by dissolving 50 mg of FL into 
1000 mL of de-ionized water. Dilute the resulting solution into several 
different concentrations for the standard curve, then analyze with a Tecan 
Infinite 200 microplate reader (Tecan Group Ltd., Männedorf, Switzerland) 
(excitation wavelength: 494 nm, emission wavelength: 521 nm), using the 
de-ionized water as the blank sample. The calibration curve of FL is shown 
in Figure 3.2. 
 
Figure 3.2 Standard curve of FL in DI water 
The equation of the curve is: I=318263C with the correlation coefficient 
of 0.9999, where I and C denote the intensity of fluorescence and the 
concentration of FL, respectively. 
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3.3.7 FL release quantification and data analysis 
Samples of 250 µL were placed in a 96-well microplate, and analyzed 
with a Tecan Infinite 200 microplate reader (Tecan Group Ltd., Männedorf, 
Switzerland) (excitation wavelength: 494 nm, emission wavelength: 521 nm) 
to quantify the concentration of released FL, according to the previously 
determined calibration curve. All measurements were performed in 
triplicates and release data were presented as mean ± standard deviation. 
Statistical analysis was performed using OriginPro software (OriginLab, 
Northampton, MA, USA) with significance level of p < 0.05. 
3.4    Results and discussion 
3.4.1 FL-loaded gelatin microbeads 
The influence of gelatin concentration, stirring rate and emulsifying time 
on particle size, size distribution and dispersity was already investigated in 
section 2.4.2. We observed that microbeads with large diameter were 
characterized by larger size variability; while microbeads with smaller size 
had a strong tendency to agglomerate. Eventually, medium-sized gelatin 
microbeads (particle size 13.9 ± 2.8 µm) prepared from a 10% of gelatin 
solution at stirring rate of 800 rpm for 10 min were selected as drug carriers 
for the further examinations. The mid-size bead selection was consistent 
with previous papers demonstrating that microbeads smaller than 10 µm 
generally generate higher release rates due to the large mass transfer area 
[105, 106].  
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Representative confocal image of FL-loaded gelatin microbeads prepared 
under those conditions was presented in Figure 3.3. FL-loaded microbeads 
did not reveal significant differences in particle size and shape 
(homogeneous, spherical and narrow distribution) when compared to FL-
free microbeads. 
 
Figure 3.3 Confocal microscopy image of FL-loaded gelatin microbeads 
prepared from a 10% gelatin solution (stirring rate of 800 rpm and 
emulsifying time of 10 min) 
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3.4.2 In vitro FL release from gelatin gel and gelatin 
microbeads 
 
Figure 3.4 (a) FL-loaded gelatin gel, (b) after one-day release at RT, (c) 
after one-day release at 37°C 
 
The images of FL-loaded gelatin gel before release test and after one-day 
release at RT and at 37°C were presented in Figure 3.4. After one-day 
release, the colour of FL-loaded gelatin gel changed from yellow to light 
yellow. Moreover, after 6-hour release, the colour of FL-loaded gelatin gels 
at both temperatures almost stopped changing and the extent of colour 
change of the gel at 37°C was deeper than the gel at RT, both of the 
phenomena were in accordance with the release profiles described as 
following.  
The release profiles of FL from gelatin gel in bulk (Gb) and from gelatin 
microbeads (Gm) at both temperature were compared in Figure 3.5. The 
cumulative release of FL at 37°C was significantly higher than at RT, both 
for Gb and Gm. At 37°C gelatin microbeads showed a significantly higher 
initial burst release than gelatin gel in bulk, but, eventually, the cumulative 
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release value at the plateau reached a similar value for both materials (about 
48%) after 10 hours. We noted that at 37°C, gelatin microbeads underwent a 
gel-to-solution (gel-sol) transition in a matter of minutes; while gelatin in 
bulk was completely dissolved in few hours. Cumulative releases at RT 
were 40% and 37% after 10 hours for gelatin microbeads and gelatin gel in 
bulk, respectively. In all cases, gelatin constructs had been separated by the 
surrounding medium by means of a dialysis membrane with a cut-off of 
3500 Da to prevent the dispersion of the solubilized gelatin in the release 
medium after gel-sol transition.  
 
Figure 3.5 Release profiles of FL from Gb and from Gm at RT and at 37 °C. 
 
49 
 
Even when the release profile reached the plateau, just about 50% of the 
loaded FL had been released in the surrounding medium; while more than 
50% of the loaded FL remained bound to the gelatin proteins. The findings 
are in accordance with other works [35, 39]. Acidic FL and basic gelatin 
used in our study could form polyion complexation which limited the 
amount of the free drug and reduced the efficiency [32, 35]. In a previous 
study, Liao et al.[40] reported that a non-charged drug was completely 
released from alginate within 2 h, whereas charged drug compounds showed 
sustained release up to 3 weeks.  
The possibility of an interaction between charged FL and gelatin is 
consistent with the high number of potential available basic sites in gelatin. 
Gelatin type A 300 Bloom has approximately an average molecular mass of 
100 kDa, accounting for roughly 1100 total amino acids, and about 14% of 
the total amino acid residues are reported to have a basic character (positive 
charge) [26, 107]. On these bases, it is possible to estimate that the ratio 
between total number of basic gelatin sites and FL molecules can range 
from 1000 to 10000 depending on the FL concentration. However, as the 
number of really available basic sites depends on the acid-base equilibrium 
of the solution and can vary considerably with solution characteristics (pH 
and ionic strength), it is not possible to establish a univocal correlation 
between available sites and loaded FL molecules 
It is clear that the extent of molecular interaction and chemical affinity 
between gelatin and loaded molecules depend on the physic-chemical 
characteristics of particular encapsulated molecule. As a consequence, a 
precise quantification of release efficiency and time span of sustained 
delivery of a specific active molecule has to be established case by case. 
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3.4.3 FL-loaded cross-linked alginate hydrogels with 
and without gelatin microbeads 
   
(a) (b) (c) 
  
(d) (e) 
Figure 3.6 (a) blank alginate droplets after cross-linking, (b) Alg-5, (c) Alg-
10, (d) Alg(Gm-20), (e) Alg(Gm-40). Diameter of alginate droplets was 
about 3 mm. 
 
Alginate was used as a carrier for gelatin microbeads. To model the 
release behavior of alginate in bulk, macroscopic spherical droplets of 
cross-linked alginate with a diameter of about 3 mm were prepared by 
adding dropwise alginate solution into a CaCl2 solution. In Figure 3.6, it is 
possible to qualitatively appreciate the differences between naked cross-
linked alginate droplets, alginate hydrogels directly loaded with FL, and 
alginate hydrogels carrying FL-loaded gelatin microbeads. Alginate gel 
appeared completely transparent and uncoloured (as shown in Figure 3.6 
(a)). Alginate gel directly loaded with different concentrations of FL in 
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solution (Alg-5 and Alg-10) assumed a pale green color (Figure 3.6 (b) and 
(c)). Confocal image of the cross section of Alg-5 was presented in Figure 
3.7; all the view was full of uniform green. Alginate gels encapsulated with 
FL-loaded gelatin microbeads (Alg(Gm-20) and Alg(Gm-40)) turned out to 
be opaque and whitish (Figure 3.6 (d) and (e)). As expected, by comparison 
between Alg-5 and Alg-10 or between Alg(Gm-20) and Alg(Gm-40), it was 
found that increasing FL content, the colour of alginate became more 
intensive. 
 
Figure 3.7 Confocal image of the cross section of Alg-5 
 
At this stage, a brief stirring is necessary to uniformly disperse drug-
loaded gelatin microbeads into the alginate solution. In this situation FL 
may diffuse from the gelatin microbeads into water-rich alginate solution. 
The extent of early release of FL into the alginate solution was estimated 
and accounted for 6% to 8% of the total FL content, depending on the 
mixing time (from 5 to 7 min). Most of FL was still trapped in the gelatin 
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microbeads, which was confirmed by the confocal micrograph as shown in 
Figure 3.8 (a). 
 
 
(a) 
 
(b) 
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Figure 3.8 Confocal microscopy images of FL-loaded gelatin microbeads 
(Gm) encapsulated in alginate solution and cross-linked alginate gels: (a) 
Gm in liquid alginate solution before alginate cross-linking, (b) Gm in 
alginate hydrogel immediately after cross-linking, (c) Gm in alginate 
hydrogel after 24 hours of the release test at 37°C, (d) Gm in alginate 
hydrogel after 7 days of release at 37°C (scale bar =100 μm).  
(d) 
 
(c) 
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Drug loss from gelatin/alginate mixture to CaCl2 solution during alginate 
cross-linking was equally inevitable, but accounted for less than 4% of the 
total loaded FL after 5-min of immersion. The washing stage in hexane did 
not involve any significant losses of loaded molecules, due to the limited 
solubility of FL in organic solvents. 
 
3.4.4 In vitro drug release from FL-loaded cross-
linked alginate gel  
The distribution of FL in the alginate/gelatin composite hydrogels after 
cross-linking was monitored by confocal microscopy. Representative 
confocal micrographs of sectioned alginate gels after different time intervals 
were shown in Figure 3.8. In the first stage after mixing and alginate cross-
linking, a fraction of free FL was readily released from the gelatin 
microbeads and delivered to the surrounding alginate gel (Figure 3.8 (b)). 
However, as shown in Figure 3.8 (c), after just 24 hours of release, free FL 
was completely cleared out from the alginate gel, whereas gelatin 
microbeads retained a considerable amount of FL. Even after 7 days of 
release (Figure 3.8 (d)), the signal of FL could be detected very clearly in 
gelatin microbeads; while no FL was found in the alginate matrix. These 
qualitative results are confirmed also by the release profiles. 
The release curves for alginate gels encapsulated with FL-loaded 
microbeads Alg(Gm-20) and the counterpart alginate gel loaded with free 
FL (Alg-5) are presented in Figure 3.9. It is worth to recall that overall 
Alg(Gm-20) and (Alg-5) samples were loaded with the same concentration 
of FL, equal to 5 µg of FL for mL of gel. 
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It is possible to see that composite gel allowed to significantly reducing 
the initial burst release. After 2 hours at 37 °C, Alg-5 presented an initial 
burst release of about 30% of the total loaded FL amount, while Alg(Gm-20) 
released less than 5% of the loeded FL in the same time span. A similar 
initial burst result was observed at RT. 
 
Figure 3.9 Release profiles of FL from FL-loaded gelatin microbeads 
encapsulated in cross-linked alginate (Alg(Gm-20)) and from cross-linked 
alginate directly loaded with FL in solution (Alg-5) both at 37°C and at RT. 
The net amount of FL initially loaded in both Alg(Gm-20) and Alg-5 was 
the same. 
 
The release rate of FL from the composite gel Alg(Gm-20) in the first 48 
hours was significantly lower than the release rate from Alg-5 at either 
temperature. The release efficiency (cumulative release at the plateau) was 
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considerably lower in case of Alg(Gm-20), both at 37 °C and RT. At 37°C, 
the net release of FL from Alg-5 increased rapidly and about 70% of the 
loaded drug was released 24 h after the start of the release experiment, and 
more than 95% FL was released after 5 days. In case of Alg(Gm-20), the 
cumulative release was less than 25% after 24 hours release, and, even after 
one-week of release, less than 50% was delivered. The same tendencies 
were also observed at both temperature tested.  
By comparing Figure 3.5 and Figure 3.9, it is possible to notice how the 
alginate matrix helped to extend the release time of FL from gelatin 
microbeads with a consequent marked reduction in the release kinetic. On 
the other hand, the total net cumulative release remained unchanged. At the 
same time, the addition of FL-delivering gelatin microbeads to the alginate 
drastically reduced the initial burst release found in case of alginate matrices 
loaded with free FL. According to our expectations, this reduction in burst 
release was specific to anionic drugs (or cationic drugs if gelatin type B is 
used); this does not apply to non-ionic drugs. 
Additionally, since electrostatic attraction appears to be a dominant 
factor for lowering the initial burst, the ionic strength of the release medium 
could also affect the extent of drug/gelatin interaction. As a consequence, 
the high ionic strength of extracellular fluids in in vivo conditions could 
further reduce initial burst and release rate. 
3.4.5 Effect of drug-loading concentration on the 
release profiles 
Alginate gels with or without gelatin microbeads have been compared by 
investigating the effect of different drug-loading concentrations on their 
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release profiles. As shown in Figure 3.10(a), alginate gels loaded with free 
FL (Alg-1.25, Alg-5, Alg-10) released about 80% of the total FL in 24 hours, 
and the remaining FL was almost completely delivered after 150 hours. The 
cumulative release after 150 hours was higher than 95% for all the initial 
FL-loading concentrations. 
 
 
Figure 3.10 Effect of drug loading concentration on the release profiles of 
FL at 37 °C: (a) from cross-linked alginate directly loaded with FL in 
(b) 
(a) 
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solution (Alg-1.25, Alg-5, and Alg-10), (b) from cross-linked alginate gels 
encapsulated with FL-loaded gelatin microbeads (Alg(Gm-5), Alg(Gm-20), 
and Alg(Gm-40)). 
 
The release efficiency of FL from cross-linked alginate encapsulated 
with gelatin microbeads (Alg(Gm-5), Alg(Gm-20), Alg(Gm-40)) was 
significantly lower (Figure 10(b)), and in all cases the total cumulative 
release of gelatin-loaded alginate gels after 7 days was reduced to about 
50%. On the other hand, initial burst release dropped from about 30% to 
less than 5% in the paired case of Alg-5 vs Alg(Gm-20) and Alg-10 vs 
Alg(Gm-40) and from 35% to about 15% in case of Alg-1.25 vs Alg(Gm-
20). Sustained release was extended up to 200 hours. In general, comparing 
curves in Figure 10(b), it is possible to notice that higher loading 
concentrations resulted in lower drug release rate and efficiency; this fact is 
also in line with previous reports [39, 99].  
Again, after the release process reached a steady state, just about 50% of 
the loaded FL had been released from the composite gels. This is consistent 
with the release profiles of FL from gelatin gels and microbeads presented 
in Figure 3.5. Confocal images in Figure 3.8(c) and (d) revealed that 
unreleased FL was still confined in the gelatin beads and probably bound to 
the gelatin proteins.  
3.4.6 Versatility of composite gels and fate of the 
system in vivo 
After 7 days of release, Alg(Gm-5), Alg(Gm-20), and Alg(Gm-40) 
samples were dissolved in PBS to free the remaining FL. As summarized in 
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Table 3.2, it was confirmed that more than 40% of the loaded FL was still 
trapped in the composite gels after the release. On the whole, more than 90% 
of the loaded FL was eventually detected. In addition, in this work a value 
of cumulative release at the plateau of about 50% of the loaded fluorescein 
was obtained. It is important to notice that this value is strictly dependent on 
the specific molecule that was used and the chemical affinity between 
gelatin and FL. 
 
Table 3.2 Cumulative release after 7 days and delayed release after 
accelerated alginate dissolution in PBS from Alg(Gm-5), Alg(Gm-20), and 
Alg(Gm-40). 
Sample 
Cumulative 
release after 7 
days (%) 
FL detected after 
dissolution (%) 
Total delivery   
(%) 
Alg(Gm-5) 51.3 ± 2.5 42.6 ± 2.1 93.9 ± 3.3 
Alg(Gm-20) 47.3 ± 2.3 44.2 ± 1.8 91.5 ± 2.9 
Alg(Gm-40) 43.1 ± 2.6 46.7 ± 1.9 89.8 ± 3.2 
 
In principle, release profiles and absolute value of cumulative release can 
be modulated independently, changing drug loading concentration in the 
gelatin microbeads, the alginate-to-gelatin ratio, and -- if possible -- 
temperature. This means that other molecules could have quite different 
release profiles and release efficiency before reaching the plateau. In some 
cases, almost complete release in a matter few hours was reported [41]. 
Ionically cross-linked alginate undergoes slow dissolution through ion 
exchange and is eventually absorbed by the body. As a consequence of 
alginate dissolution, gelatin and undelivered drugs are exposed to body 
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fluids. Uncross-linked gelatin then can be degraded by collagenase and 
other enzymes [108], and residual drugs bound to the gelatin can still be 
available for absorption.  
In this study, we proposed to use a cross-linkable alginate solution as a 
carrier for drug-loaded gelatin microbeads. It has been previously reported 
that delayed cross-linking can be obtained with a number of different 
strategies [53, 60]. In some cases, alginate persists in a solution state long 
enough for the injection process to be completed; in other cases the forming 
alginate gel maintains a viscosity compatible with needle injection. In the 
present work, we used a fast gelation process to obtain consistently well-
controlled alginate macroscopic spheres.  
In fact, a well-controlled geometry was necessary to generate comparable 
and reproducible release data. However, considering that alginate gelation 
mechanisms are not influenced by the presence of gelatin, this drug-loading 
strategy could be applied to the previously demonstrated injectable alginate 
formulations. 
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3.5    Conclusions 
A novel drug delivery system was demonstrated by encapsulating 
uncross-linked gelatin microbeads into a cross-linkable alginate matrix. The 
preparation of this composite hydrogel is extremely straightforward, fast 
and inexpensive; thanks to the mild operating conditions and the versatility 
of gelatin, virtually any hydrophilic drugs and molecules can be easily 
incorporated. The encapsulation of gelatin microbeads in the cross-linked 
alginate allowed a drastic reduction of initial burst release, while extending 
the sustained release of fluorescein up to 200 hours. Release profile can be 
easily modulated by varying drug-loading concentration in the gelatin 
microbeads, the alginate-to-gelatin ratio, and temperature. These results 
suggested that this alginate-gelatin composite hydrogel represented a 
potential improvement for self-cross-linking and injectable drug delivery 
system. 
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Chapter 4   
Dual drug delivery system of gelatin 
microbeads embedded in alginate 
4.1     Introduction 
 
Since the first drug delivery system (DDS) was approved by FDA in 1989, 
DDS has been widely explored in the development of medicine and 
healthcare [73]. By using a DDS, especially sustained or slow drug delivery 
system, drug could be transported to the targeted site at predefined dose and 
time. Meanwhile, side-effect of tissue damage on extravasation, especially 
from high drug loading, could be reduced significantly. As a result of using 
DDS, problems such as poor solubility, poor biodistribution and rapid 
breakdown of the drug in vivo could be avoided effectively [5, 109]. 
However, because of diversification and complication of diseases and tissue 
reborn, the ability to deliver multiple drugs is often a pivotal factor to the 
efficacy of therapy.  
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For instance, after the orthopaedics and implant surgery, the therapies 
with multiple drugs are predominantly crucial to prevent bacterial infections, 
anti-inflammation, and improve osseo-integration or bone recovery [110-
112]. Transporting multiple drugs in a system has been investigated 
increasingly and intensively. By employing various drugs at optimal dose 
and specific periods during the treatment, it would help DDS to reach the 
optimized effect and satisfy the needs in clinical therapies [113, 114]. 
Furthermore, different drugs for multiple-purpose therapy are also required 
in pharmaceutical and biomedical applications [66-69, 115]. In order to get 
optimal therapeutic effect of different drugs, the most important thing which 
should be considered is how to control release behaviour of each drug 
independently.  
In this study, the composite of uncross-linked gelatin microbeads and 
cross-linked alginate was fabricated and used as dual drug delivery system, 
as shown in Figure 4.1. Based on our previous study[116], the synergistic 
interplay between the two components overcomes the limitations of 
individual component. Gelatin microbeads assist alginate to suppress the 
burst release and extend the duration of drug delivery; cross-linked alginate 
prevents gelatin microbeads from being immediately dissipated upon 
melting in vivo. In present study, two hydrophilic model drugs, Fluorescein 
(FL) and Rhodamine-B (RhB), were chosen to be encapsulated into alginate 
matrix and gelatin microbeads, respectively. These small fluorescent 
molecules are widely used as drug models for their ease to detect and are 
comparable with many chemotherapeutic drugs[104, 117].  
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Figure 4.1. Schematic representation of the preparation of gelatin 
microbeads/alginate composite hydrogel and drug release. 
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RhB-loaded gelatin microbeads were first prepared and then dispersed in 
the aqueous solution of sodium alginate and FL. The resulting suspension 
was cross-linked upon the addition of calcium chloride solution to obtain the 
cross-linked composite hydrogel for dual drug delivery. The effects of drug-
loading method of gelatin microbeads and the ratio between gelatin 
microbeads and alginate solution on the release profiles were studied. This 
composite hydrogel may show a broad application in multiple-drug delivery 
systems. 
 
4.2    Materials 
 
Gelatin (type A, from porcine skin), Sodium Alginate (Alginic acid 
sodium salt from brown algae), Fluorescein (FL) with green fluorescence, 
Rhodamine-B (RhB) with red fluorescence, Calcium Chloride, Trizma base, 
hydrochloric acid, soybean oil, nonionic surfactant sorbitane monooleate 
(Span 80) and n-Hexane were all purchased from Sigma-Aldrich (Milan, 
Italy). All the materials were used as received without further puriﬁcation. 
 
4.3    Methods 
 
4.3.1 Preparation of RhB-loaded gelatin microbeads 
A 10% (w/v) gelatin aqueous solution was prepared by dissolving gelatin 
powder (type A) in de-ionized water (DI water) at 40°C for 30 min. RhB 
was mixed directly into the 10% (w/v) gelatin solution to obtain a 6 µg/mL 
RhB concentration.  
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Gelatin microbeads loaded with RhB were prepared by an emulsification 
method as described previously [116]. Briefly, 1 mL of RhB-loaded aqueous 
gelatin solution at the concentration of 10% (w/v) was added to 5 mL of 
soybean oil containing 100 mg of Span 80 while stirring at 800 rpm for 10 
min in a 10-mL beaker with an 8-mm magnetic stir bar in a 40°C water bath. 
The resulting water-in-oil emulsion was further stirred at 200 rpm for 30 min 
in an ice-bath for complete gelation of gelatin microbeads. The microbeads 
were washed five times with sufficient n-hexane and subsequently placed in 
a vacuum drier overnight to remove n-hexane. RhB-loaded microbeads 
produced with this process were identified as GM-1.  
In addition, GM-1 microbeads were also frozen in liquid nitrogen and de-
hydrated by freeze-drying to obtain RhB loaded gelatin microbeads in dry 
state (hereinafter identified as GM-2).  
In alternative, also RhB-free gelatin microbeads were produced starting 
from 10% gelatin solution without any dyes. In this case, RhB was loaded 
into the microbeads by immersing blank freeze-dried gelatin microbeads into 
a 6 μg/mL aqueous solution of RhB overnight (hereinafter identified as GM-
3). All the samples were summarized in Table 1. 
 
4.3.2 Morphology of gelatin microbeads  
Confocal images of RhB-loaded gelatin microbeads in oily phase were 
taken with laser confocal microscope (Nikon A1, Tokyo, Japan). Surface 
morphology of gelatin microbeads was observed by scanning electron 
microscopy (SEM) (FESEM Field Emission Scanning Electron Microscope, 
ZEISS SUPRA™ 40, Göttingen, Germany). After freeze-drying, gelatin 
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microspheres were attached to the specimen stage with a double-side tape, 
and then spray-coated with gold at 0.6 kV before observation under the 
electron microscope.  
 
4.3.3 Preparation of FL-loaded cross-linked alginate 
gels 
 
Table 4.1 Samples prepared and their respective compositions 
Sample code Description  
GM/GB gelatin microbeads/ gelatin gel in bulk 
GM-1 unfreeze-dried RhB-loaded GM 
GM-2 freeze-dried RhB-loaded GM 
GM-3 RhB-loaded GM by immerse free-loaded freeze-dried 
GM into RhB solution 
Alg FL-loaded alginate without GM 
Alg(GM-1) FL-loaded alginate encapsulated with unfreeze-dried 
RhB-loaded GM  
Alg(GM-2) FL-loaded alginate encapsulated with freeze-dried RhB-
loaded GM 
Alg(GM-3) Immerse free-loaded freeze-dried GM into RhB solution, 
then mix with FL-loaded alginate and crosslink  
2-Alg(GM-1) FL-loaded alginate encapsulated with unfreeze-dried 
RhB-loaded GM, the same as GM-1, but with double 
alginate 
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A 1.5% (w/v) alginate aqueous solution was prepared by dissolving 
sodium alginate powder in DI water at RT under mild agitation for 2 h and 
then moved to an ice bath.  
FL was first mixed directly in the 1.5% (w/v) alginate solution to obtain a 
FL concentration of 5 µg/mL. Then, previously prepared RhB-loaded gelatin 
microbeads (GM-1, GM-2 and GM-3) were uniformly dispersed into the 
FL/alginate solution by continuous stirring for 5 min in the ice bath. After 
stirring, 3% (w/v) CaCl2 aqueous solution was immediately added on the top 
of the suspension. This made alginate cross-link and generated FL-loaded 
macroscopic alginate bulk carrying RhB-loaded gelatin microbeads. 
Composite gels carrying different GMs in this process are hereinafter named 
Alg(GM-1), Alg(GM-2), and Alg(GM-3). For comparison, FL-loaded 
alginate gels without gelatin microbeads named Alg and double volume of 
FL-loaded alginate gels carrying the same amount of GM-1 as in Alg(GM-1) 
named 2-Alg(GM-1) were also prepared. All the samples and compositions 
were summarized in Table 4.1.  
 
4.3.4 Preparation of Tris-HCl buffer (pH=7.4) 
To make a 1.0 M Tris buffer solution with pH equal to 7.4, 121.1g of 
Trizma base was added to 800 mL of DI water under mild agitation, after 
the temperature cooled down to RT, adjust the pH to 7.4 using 0.1 M 
hydrochloride. Finally, make the total volume of the buffer solution to 1 L 
by adding DI water. This solution could be stored at RT. 
69 
 
4.3.5 In vitro drug release from RhB-loaded gelatin 
gel and gelatin microbeads 
To study the different drug release behaviors of RhB-loaded gelatin gel 
and gelatin microbeads, both of them were prepared from 1 mL gelatin 
aqueous solution containing 6 µg/mL RhB and then were filled into a 3 
mm dialysis tubes (Regenerated cellulose dialysis membrane, MWCO 
3500, Spectra/Por
®
, Spectrum Lab., CA, USA). Each dialysis tube was 
immersed in 10 mL of Tris-HCl buffer solution (pH=7.4) under mild 
agitation. The release experiment was performed at 37 ± 1°C. At 
predetermined time intervals, 1 mL of release medium was extracted and 
replaced by 1 mL fresh medium. All the extracted samples were stored at 
4°C in dark until all the time points were collected.  
4.3.6 In vitro drug release from FL-loaded cross-
linked alginate gels 
Different drug release studies from alginate gels with various components 
were conducted by adding 2 mL Tris-HCl buffer solution to a vial containing 
alginate gel. The release experiment was performed at 37 ± 1°C. 1 mL 
release medium of each sample was collected at predetermined time 
intervals for fluorescence intensity test and the same amount of Tris-HCl 
buffer solution was added. The collected samples were stored at 4°C in dark 
until all the time points were collected. Drug distribution in the composite 
hydrogel (Alg(GM-1)) at different release stage was monitored during the 
release experiment by confocal microscope. 
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4.3.7 Calibration curve of FL and RhB in Tris-HCl 
buffer (pH=7.4) 
FL and RhB were separately dissolved into Tris-HCl buffer solution at a 
concentration of 50 mg/L to prepare the stock solutions of FL and RhB. The 
resulting solution was diluted into several different concentrations for the 
standard curve, then analyzed with a Tecan Infinite 200 microplate reader 
(Tecan Group Ltd., Männedorf, Switzerland) (excitation wavelength: 494 
nm, emission wavelength: 521 nm for FL; excitation wavelength: 560 nm, 
emission wavelength: 590 nm for RhB), using the Tris-HCl buffer solution 
as the blank sample. The calibration curves of FL and RhB are shown in 
Figure 4.2 and Figure 4.3. 
 
Figure 4.2 Standard curve of FL in Tris-HCl buffer solution 
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The equation of the curve is: I=81265C+1150 with the correlation 
coefficient of 0.9999, where I and C denote the intensity of fluorescence and 
the concentration of FL, respectively. 
 
Figure 4.3 Standard curve of RhB in Tris-HCl buffer solution 
 
The equation of the curve is: I=222852C-255 with the correlation 
coefficient of 0.9999, where I and C denote the intensity of fluorescence and 
the concentration of RhB, respectively. 
 
4.3.8 Drug release quantification 
Samples of 250 µL were placed in a 96-well microplate, and analyzed 
with a Tecan Infinite 200 microplate reader (Tecan Group Ltd., Männedorf, 
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Switzerland; excitation wavelength: 494 nm, emission wavelength: 521 nm 
for FL; excitation wavelength: 560 nm, emission wavelength: 590 nm for 
RhB) to quantify the concentration of released FL and RhB, according to the 
previously determined calibration curves, using the Tris-HCl buffer solution 
as the blank sample. All measurements were performed in triplicates. 
4.3.9 Data analysis 
All release experiments were carried out with at least three samples and 
all data were presented as mean ± standard deviation. Statistical analysis was 
performed using OriginPro software (OriginLab, Northampton, MA, USA) 
with significance level of p < 0.05. 
4.4    Results and Discussion 
4.4.1 Characterization of gelatin microbeads 
It is well-known that morphology of the materials would be an 
appreciable factor in the drug release system [118]. The surface morphology 
of uncross-linked, freeze-dried gelatin microbeads was shown in Figure 
4.4(a) and (b) in different magnifications. In Figure 4.4(a), an irregularly-
shaped morphology of gelatine particles system was obtained due to the lack 
of crosslinking procedure. Lee [31] observed that the crosslinking process 
helps to shape the gelatin particles into a uniformly round morphology by 
the self-aggregation of gelatin particles. Those particles prepared in absence 
of crosslinking process display random morphology due to their inter-
particle aggregation. Figure 4.4(b) presents the magnified morphology of 
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one single gelatin particle. Due to freeze-drying treatment, the losing of 
water made gelatin particle become porous, which we assume would led to 
fast drug diffusion from gelatin matrix according to Patel’s study [119].  
 
  
 
Figure 4.4 Scanning electron microscopic images of gelatin microbeads in 
low (a) and high magnification (b). 
(a) 
 
(b) 
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A representative confocal image of RhB-loaded gelatin microbeads in the 
oily phase was presented in Figure 4.5. From the figure we can see that the 
gelatin microbeads are spherical shaped in relatively uniform size 
distribution with an average diameter of 30 m and the intensity of 
fluorescence is very strong. 
 
 
Figure 4.5 Confocal microscopy image of RhB-loaded gelatin microbeads 
(scale bar= 100 μm). 
 
4.4.2 In vitro RhB release from gelatin gel and gelatin 
microbeads 
The release profiles of RhB from gelatin gel in bulk (GB) and from 
gelatin microbeads (GM) at 37°C were compared in Figure 4.6. RhB release 
from gelatin microbeads was slightly faster than that from bulk gelatin gel 
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during the first four hours, which was followed by a similar increasing 
tendency until a plateau (about 62%) was reached in both systems at 10 
hours. We notice that at 37°C, bulk gelatin gel needs longer time than gelatin 
microbeads to undergo gel-sol transition, which can be assumed as the 
reason for the release difference in the first four hours. Then both of them 
reached the melt state under the same condition, that’s why the two release 
curves almost overlap after four hours as shown in Figure 4.6. When release 
profile reached the plateau, the accumulative release percent of RhB was 
about 62%, which means about 38% of the loaded RhB still remained bound 
to the gelatin matrix for sustained and slow release. Similarly in our previous 
study, about 52% of the loaded FL was bonded to gelatin matrix [116], 
which suggests that the strength of the interaction deponds on the type of 
drugs used. According to Ofner’s study [42], the duration of rapid release 
depends on the strength of interaction between gelatin and drug loaded. 
Gelatin contains a large amount of carboxyl, amide and amino groups, which 
would form different conjugates with different drugs. It is clear that the 
stability of the conjugates mainly depends on the molecular interaction and 
chemical affinity between gelatin and loaded drug. Moreover, prolonged 
drug impregnation increases the amount of drug complexed with gelatin [32]. 
In the case of our study, gelatin-RhB conjugate would reduce the amount of 
free drug to about 60%, therefore slow down the release rate of the rest drug, 
which is in accordance with other works [31, 32, 39, 40, 116].  
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Figure 4.6 Release profiles of RhB directly from GM and GB at 37 °C. 
 
4.4.3 In vitro dual drug release from alginate/gelatin 
composite 
At the stage of adding gelatin microbeads into alginate solution in an ice-
bath, a fast stirring was necessary to uniformly disperse drug-loaded gelatin 
microbeads into alginate solution. Sample Alg(GM-1) containing different 
dyes (FL: green, in alginate; RhB: red, in gelatin microbeads) was observed 
at different period under confocal microscopy (Figure 4.7). Images in Figure 
4.7A were taken before cross-linking. As shown in Figure 4.7(A-1), gelatin 
microbeads had a strong tendency to agglomerate [31]. The fluorescent 
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strength of FL in alginate solution where more gelatin microbeads contained 
was much stronger than where fewer gelatin microbeads existed because free 
FL tend to absorb on the surface of gelatin microbeads. This happens due to 
the fact that acidic FL could form stronger bonding with basic gelatin 
compared with the interaction between acidic FL and acidic alginate [41]. 
However, Figure 4.7(A-2) shows that fluorescence of RhB could be 
observed only in the gelatin microbeads instead of alginate solution, which 
indicates that the level of RhB released from gelatin microbeads to alginate 
solution was undetectable and RhB form stable bonding with gelatin. When 
fluorescence of FL and RhB were detected simultaneously as shown in 
Figure 4.7(A-3), the colour of gelatin microbeads turned from red  shown in 
Figure 4.7(A-2) to yellow, which is one of the overlaid colour of red (RhB) 
and green (FL). This phenomenon further confirmed the absorption of FL by 
gelatin microbeads shown in Figure 4.7(A-1).  
Drug loss from gelatin/alginate mixture to CaCl2 solution during alginate 
cross-linking was inevitable, less than 3% of RhB and more than 20% of FL 
was detected, which were taken into consideration during calculation of their 
cumulative release. 
Drug redistribution after two hours release in Tris-HCl buffer was 
presented in the images of Figure 4.7B. As shown in Figure 4.7(B-1), the 
background turned out to be lighter and more uniform in colour intensity, 
which suggests most of the FL was released. However, the concentration of 
FL in gelatin microbeads was still slightly higher than that in alginate gel, 
which indicates that FL could have stronger bonding with gelatin than with 
alginate [41, 42].  
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Figure 4.7 Confocal microscopy images of drug distribution at different 
release stage of composite hydrogel Alg(GM-1). 
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From Figure 4.7(B-2), we can see that most gelatin microbeads were still 
spherical but the colour of gelatin microbeads became lighter than those in 
Figure 4.7(A-2). We can assume that gel-sol transition of gelatin microbeads 
was still in process and the release of RhB just commenced. Due to the fact 
that both drugs can form more stable complex with gelatin than with alginate, 
after 24 hours release, the background of alginate gel became dark and weak 
green could be observed only in gelatin microbeads. Meanwhile, the shape 
of gelatin microbeads already turned to irregular, while the fluorescence of 
RhB in gelatin microbeads was still strong enough to monitor. Even after 6 
days release (Figure 4.7(D-2)), the residual RhB could be apparently 
detected. However, by comparing Figure 4.7(D-2) with Figure 4.7(D-3), 
little difference could be recognized, which states that little FL was bonded 
to gelatin microbeads and was not capable of affecting the appearance of 
RhB. These qualitative results were confirmed also by the release profiles. 
 
4.4.4 The comparison of two release profiles of FL 
and RhB 
The release profiles of two drugs (FL and RhB) in sample Alg(GM-1) 
are shown in Figure 4.8. The two profiles have the similar release tendency 
but with quite different release percentage. With different bonding strength 
between drug and matrix, less than 40% of RhB was released after 24 hours; 
while more than 80% of FL was released out. From the comparison of 
confocal images shown in Figure 4.7, it was conformed that the 20% of 
residual FL was bonded to the gelatin microbeads instead of alginate matrix. 
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From 24 hours onwards, both FL and RhB were released slowly and 
continuously. Only 3% of FL and 7% of RhB were detected from the release 
buffer. However, with the dissolution of alginate matrix and the degradation 
of gelatin microbeads in the body, the release rate of the residual drugs 
would be fastened. 
 
 
Figure 4.8 The comparison of two release profiles of FL and RhB from the 
sample Alg(GM-1). 
 
4.4.5 Effect of loading ratio of gelatin microbeads on 
drug release profiles 
The cumulative release curves of RhB from Alg(GM-1) and the 
counterpart with double amount of FL-loaded alginate gel 2-Alg(GM-1) are 
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presented in Figure 4.9, and the enlarged release profile during the first 8 
hours is given in the inset of Figure 4.9. As reported [66, 118], drug loading 
amount would affect the drug release profile and high drug loading resulted 
in slower release, which is also proved in Figure 4.9. It could be seen that the 
tendency of both release profiles were similar, but the release rate of 2-
Alg(GM-1) was faster than that of Alg(GM-1). This could be attributed to 
the change of drug diffusivity caused by the different drug loading levels and 
the varied microstructure in the composite. In addition, it was observed that 
more than 30% of loaded RhB was released in the first 8 hours, which 
estimated that not all the RhB molecules were ionically complexed with 
gelatin microbeads. It is probable that the non-complexed RhB was released 
by diffusion during the initial period of release [11, 16, 32, 65]. From day 
one onwards, the release was gradual and sustained. Approximately, 42% of 
the encapsulated RhB was released from Alg(GM-1) by day 6, which 
consistent with what was shown in confocal images.  
By comparing with the release profile of GM in Figure 4.6, it is possible 
to notice that composite gel significantly reduced the RhB release rate and 
extended the release time. Only 10 hours was needed for alginate-free GM to 
reach the release plateau (62%). In comparison, less than 50% of loaded 
RhB was released from gelatin microbeads embedded with alginate matrix 
even after 6 days. As reported by Almeida et al, the change in the matrix 
structure would led to different release behaviour [120]. 
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Figure 4.9 Effect of drug-loaded gelatin microbeads ratio on RhB release 
profiles of Alg(GM-1) and 2- Alg(GM-1). 
 
It is reported that higher microbeads/matrix ratio resulted in faster drug 
release from matrix, which may be due to the interference introduced by 
microbeads to the matrix [66]. As shown in Figure 4.10, the release rate of 
microbeads-free alginate matrix (Alg) showed faster releasing rate than 
microbeads-loaded Alg(GM-1) and 2-Alg(GM-1), which was ascribed to the 
absence of gelatin microbeads. If there was no interaction between gelatin 
microbeads and FL, the FL release rate of Alg should be the lowest 
according to previous discussion. However FL forms bonding with gelatin 
microbeads, which slowed down the diffusion of FL from alginate matrix to 
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the buffer and then reduced the FL release rate of Alg(GM-1) and 2-
Alg(GM-1). From the release curve of Alg(GM-1), it could be found that the 
release was fast in the first 2 hours with accumulative release of 70% FL. 
Cumulative release percent of FL till day 1 was approximately 85%, 
followed by a slow and sustained release till day 6, which could well 
illustrate the changes from Figure 4.7A to Figure 4.7D. The fast release 
before day 1 was mainly from the FL-alginate complex since the bonding 
between FL and alginate was weak. Nevertheless, the following slow release 
was from FL-gelatin complex, which was more stable. 
 
Figure 4.10 Effect of drug-loaded gelatin microbeads ratio on FL release 
profiles of Alg, Alg(GM-1) and 2- Alg(GM-1). 
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4.4.6 Effect of drug-loading methods of gelatin 
microbeads on drug release profiles 
The effect of different preparation methods of drug-loaded gelatin 
microbeads on RhB and FL release profiles was studied. As shown in Figure 
4.11, the cumulative release of RhB from Alg(GM-2) and Alg(GM-3) was 
much faster than that from Alg(GM-1). This could be explained by the fact 
that there was insufficient liberated water to dissolve freeze-dried gelatin 
micorbeads when encapsulated in the cross-linked alginate matrix. This 
resulted in rather weak bonding between RhB and freeze-dried gelatin 
microbeads in Alg(GM-2) and Alg(GM-3). Therefore, loaded RhB could 
cast off the bonding with gelatin easily and diffuse to the surrounding buffer. 
In addition, since the drug was loaded on Alg(GM-3) just by simple 
absorption, majority of the loaded RhB was concentrated on the surface of 
freeze-dried gelatin microbeads, which generated the fastest release among 
the three samples within first 24 hours. 
85 
 
 
Figure 4.11 Effect of preparation method of drug-loaded gelatin microbeads 
on RhB release profiles of Alg(GM-1), Alg(GM-1) and Alg(GM-3). 
 
FL release profiles from the three samples were demonstrated in Figure 
4.12. Obviously, an initial quick release followed by a slow and sustained 
release was observed. As described above, release rate of RhB from 
Alg(GM-3) was the fastest, which implied the available sites for bonding FL 
increased. Therefore, just 75% of loaded FL was released even after 6 days 
compared with 80% of Alg(GM-2) and 85% of Alg(GM-1). 
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Figure 4.12 Effect of preparation method of drug-loaded gelatin microbeads 
on FL release profiles of Alg(GM-1), Alg(GM-1) and Alg(GM-3). 
 
To summarize the releasing kinetics of independent drug in various 
systems, we can conclude that release rate of FL decreases in order: 
Alg>Alg(GM-1)> 2-Alg(GM-1)>Alg(GM-2)>Alg(GM-3) while RhB 
exhibits distinguished sequence: Alg(GM-3)>Alg(GM-2)>2-Alg(GM-
1)>Alg(GM-1). Both FL and RhB present similar releasing tendency in 
Alg(GM-3). So from matrix point of view, it is reasonable to infer that 
Alg(GM-1) displays the most significant difference between the release of 
FL and RhB. 
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Although all the results in our experiment were based on the model drugs, 
this dual drug release technology seems to be applicable for many drugs or 
growth factors. Any charged molecules could be embedded in gelatin 
microbeads for sustained release since it is theoretically possible for gelatin 
to form polyion complexes with charged molecules, and another drug 
blended in alginate solution could be used for fast release. As for the 
practical application, after injecting or implanting the composite of gelatin 
and alginate into the body site, a slow dissolution of cross-linked alginate 
following the fast release would occur by removing the cross-linking ions in 
vivo, and then the remaining drugs bound with the gelatin microbeads would 
be released when gelatin microbeads lose the “protection” of alginate gel. 
Depending on the demand of practical application, adjusting the 
concentration of alginate gels would change the degradation time of alginate 
gels [49].  
 
4.5 Conclusions 
 
In this study, a dual-drug delivery system was fabricated by embedding 
gelatin microbeads within alginate matrices. The two components in the 
system helped to overcome the limitations of both alginate and gelatin gels 
in applications. The dual-drug release test in vitro showed quite different 
release profiles between FL loaded in alginate and RhB loaded in gelatin 
microbeads. The release profile of RhB illustrated a low initial release burst 
and cumulative release percent. Decreasing the ratio of RhB-loaded gelatin 
microbeads in alginate would increase the release of RhB and reduce the 
release of FL. In addition, RhB-loading method of gelatin microbeads had 
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significant influence on the release behaviour of both drugs. Moreover, 
gelatin microbeads after freeze-dry will shorten the difference between the 
release of FL and RhB. As a summary, the aim of this paper is to provide an 
idea for the field of dual drug delivery system, all the study is focused on the 
research in lab-scale which can be regarded as valuable reference for the 
practical application. 
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Chapter 5 
Multi-drug delivery system of 
gelatin layers using agarose as 
diffusion barriers 
 
5.1    Introduction 
 
With the increase of the variety and complexity of diseases, multi-drug 
delivery system will be needed more and more in the future. Although 
loading individual drugs into conventional drug delivery systems has 
demonstrated to be a simple and efficient way, many disadvantages have 
come out, such as toxicity, poor bioavailability and bio-distribution [109, 
121]. Supported by the results of chapter 3 and chapter 4, drug delivery 
systems based on gelatin turned to be a polymer-drug conjugates, where a 
drug would be covalently attached to gelatin to improve its therapeutic 
performance [122, 123].  
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The main improvement of multi-drug therapy over mono-drug therapy is 
the ability to delivery drugs to different disease as needed simultaneously, 
which results in increased activity and reduced toxicity [124, 125]. Moom et. 
al fabricated a multi-drug delivery system with sequential release based on 
the titania nanotube arrays in 2012 [126]. 
The aim of this chapter is to provide an idea for the multi-drug delivery 
system, although it is still immature for the application in vivo. Here, we 
prepared the multi-drug delivery system of gelatin layers by using agarose 
as the diffusion barriers, which is easy to prepare and doesn’t need any 
organic solvent. Based on the performances of gelatin described in previous 
chapters, a series of gelatin layers loaded with different drugs were 
separated by the rods of agarose in a polycarbonate tube. With the change of 
the order of drug-loaded gelatin layers and the length of the rod of agarose, 
or temperature, different release profiles of multiple drugs could be obtained. 
However, for the device, it should be micro-sized, or at least millimeter-
sized if using in the human body. In our experiment, we just preliminarily 
focused on the release effect with centimeter-sized device. 
5.2    Materials 
Gelatin (type A, from porcine skin), Agarose, Fluorescein (FL) with 
green fluorescence, Rhodamine-B (RhB) with red fluorescence, PBS buffer 
powder were all purchased from Sigma-Aldrich (Milan, Italy). All the 
materials were used as received without further puriﬁcation. 
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5.3    Methods 
5.3.1 Preparation of agarose solution and drug-
loaded gelatin solution 
A 2% (w/v) agarose aqueous solution was prepared by dissolving 
agarose powder in de-ionized water (DI water) at 95°C for 30 min, then 
cooled down to 50°C ready for use. 
A 10% (w/v) gelatin aqueous solution was prepared by dissolving gelatin 
powder (type A) in de-ionized water (DI water) at 40°C for 30 min. FL and 
RhB were mixed directly into the 10% (w/v) gelatin solution to obtain the 
concentration of 20 µg/mL of FL and 6 µg/mL of RhB, separately.  
5.3.2 Preparation of the multi-drug delivery device 
and system 
A hollow polycarbonate tube with sealed bottom was chosen as the drug 
delivery device. 200μL of RhB-loaded gelatin solution was injected into the 
bottom of the tube slowly. After the gelation of gelatin solution, a 
membrane of aluminum was put on the top of the gelified gelatin gel. There 
were several holes in the aluminum membrane. 
The agarose solution was poured into the same type of polycarbonate 
tube. After the gelation, the gelified agarose gel was taken out and cut into 
pieces with different length, using as the diffusion barriers. A gelified 
agarose gel rod was put on the aluminum membrane. 
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Then another 200μL of FL-loaded gelatin solution and a gel rod of 
agarose were loaded into the tube one after another by the same method 
described as above.  
To prevent the agarose gel going down after gelatin gel melted at body 
temperature, an aluminum membrane was put between each two layers. 
Finally, 2 mL of PBS buffer solution was added into the top of the second 
rod of agarose gel and then sealed with a film. The schematic diagram and 
the real picture of multi-drug delivery system were presented in Figure 5.1 
and Figure 5.2. 
 
Figure 5.1 Schematic diagram of multi-drug delivery system. 
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Figure 5.2 Picture of multi-drug delivery system 
 
In this experiment, two factors were studied, temperature and the length 
of agarose gel; therefore, three different samples were prepared: two with 1 
cm-length agarose gel, at different temperature (37°C and RT); another one 
with 2 cm-length agarose gel at 37°C. All the samples and compositions 
were summarized in Table 5.1. 
 
Table 5.1 Samples prepared and their respective compositions 
Sample code Description  
L-FL FL-loaded gelatin gel in the tube with 2 cm-length 
agarose gel at 37°C 
L-RhB RhB-loaded gelatin gel in the tube with 2 cm-length 
agarose gel at 37°C 
S-FL FL-loaded gelatin gel in the tube with 1 cm-length 
agarose gel at 37°C 
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S-RhB RhB-loaded gelatin gel in the tube with 1 cm-length 
agarose gel at 37°C 
S-FL-RT FL-loaded gelatin gel in the tube with 1 cm-length 
agarose gel at RT 
S-RhB-RT RhB-loaded gelatin gel in the tube with 1 cm-length 
agarose gel at RT 
 
5.3.3 In vitro drug release 
The release tube was inserted into a cube of polyurethane to protect the 
temperature change inside of the release tube, and then put into different 
temperature environment. 1 mL release medium of each sample was 
collected at predetermined time intervals for fluorescence intensity test and 
the same amount of PBS buffer solution was added. The collected samples 
were stored at 4°C in dark until all the time points were collected.  
5.3.4 Calibration curve of FL and RhB in PBS buffer 
solution (pH=7.4) 
The stock solutions of FL and RhB were prepared by dissolving 50 mg of 
FL and 50 mg of RhB into 1000 mL of PBS buffer solution, respectively. 
Dilute the resulting solution into several different concentrations for the 
standard curve, then analyze with a Tecan Infinite 200 microplate reader 
(Tecan Group Ltd., Männedorf, Switzerland) (excitation wavelength: 494 
nm, emission wavelength: 521 nm for FL; excitation wavelength: 560 nm, 
95 
 
emission wavelength: 590 nm for RhB), using the PBS buffer solution as 
the blank sample. The calibration curves of FL and RhB are shown in 
Figure 5.3 and Figure 5.4. 
 
Figure 5.3 Standard curve of FL in PBS buffer solution 
The equation of the curve is: I=69453C+311 with the correlation 
coefficient of 0.9998, where I and C denote the intensity of fluorescence and 
the concentration of FL, respectively. 
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Figure 5.4 Standard curve of RhB in PBS buffer solution 
 
The equation of the curve is: I=102350C-109 with the correlation 
coefficient of 0.9987, where I and C denote the intensity of fluorescence and 
the concentration of RhB, respectively. 
 
5.3.5 Drug release quantification and data analysis 
This section is similar to section 4.3.8 and 4.3.9, with the only difference 
of using the PBS buffer solution as the blank sample. 
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5.4    Results and Discussion 
5.4.1 Effect of length of agarose gel on the release 
profiles 
 
Figure 5.5 Effect of length of agarose gel on the release profiles of FL and 
RhB at 37°C 
The effect of length of agarose gel on the release profiles was shown in 
Figure 5.5. By the comparison between L-FL and S-FL or between L-RhB 
and S-RhB, it could be concluded that with the increase of the length of 
agarose gel, the release rate of drug from the upper layer or lower layer was 
decreased. It could be attributed to the difference of drug diffusion rate 
through the rod of agarose gel. Therefore, according to the different 
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requirement of drugs loaded in the multi-drug delivery tube, it is easy to 
meet the needs just by adjusting the length of each agarose gel.  
In addition, from the figure we also can see, both FL and RhB showed a 
sustained release profile, while the release rate of FL (the upper layer of 
gelatin gel) was faster than that of RhB (the lower layer of gelatin gel), 
which estimated that with the different depth of drug-loaded gelatin layer, 
the drug release rate was different. Therefore, multi-layers of different drug-
loaded gelatin gel could be prepared in this multi-drug delivery tube for 
multi-drug delivery with different release profiles. 
5.4.2 Effect of temperature on the release profiles 
 
Figure 5.6 Effect of temperature on the release profiles of FL and RhB with 
1 cm-length agarose gel 
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The effect of temperature on the release profiles was presented in Figure 
5.6. The significant difference between the release profiles at RT and 37°C 
could be observed, no matter FL or RhB. As a matter of fact, gelatin gel was 
still in solid state when the multi-drug delivery system was placed at RT, it 
is quite difficult for the molecules of drugs to diffuse through solid gel; 
while gelatin gel would melt when placed at 37°C, which would accelerate 
the diffusion of drugs from melted gelatin solution. 
 
5.5    Conclusions 
A novel and simple model of multi-drug delivery system was designed 
and fabricated by putting the rods of agarose gel and drug-loaded gelatin gel 
into a polycarbonate tube layer by layer. The gelatin-drug conjugate 
(chapter 3 and 4) was still the key factor in this system. The length of 
diffusion barriers (agarose gel) and temperature had great influence on the 
release profiles of both drugs, no matter in upper gelatin layer or in lower 
gelatin layer. Operating in a similar way, multiple drugs could be loaded 
into gelatin gel separated by agarose layers. However, this chapter just 
provides an idea for multi-drug delivery system, more effort to put this 
system into practical application is worthwhile, especially in the aspects of 
the dimension and material of the device (tube and membrane). As for the 
dimension, it should be suitable for the practical application (ultimately in 
vivo), micro-sized or millimeter-sized is preferable. And as for the material, 
it should be biodegradable and biocompatible, at least, non-toxic to the body, 
like titania nanotube, already used by Moom [126]. 
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Chapter 6 
Final Remarks 
6.1    Conclusions 
This thesis investigated the production of drug delivery system based on 
the uncross-linked gelatin. The main results are as following: 
First, based on the study of all the preparation parameters, the optimal 
condition for the preparation of gelatin microbeads is: 100 μg/mL (10%) 
gelatin solutions, 1: 5 of water/oil volume ratio, 10 min of emulsifying time 
and 800 rpm of the stirring speed. 
Then, a novel drug delivery system consisting of drug-loaded uncross-
linked gelatin microbeads and cross-linkable alginate matrix was fabricated. 
The drug release profile was studied, which showed a drastic reduction of 
initial burst release and a sustained release up to 200 hours by the 
synergistic interplay between gelatin and drug. Release profile can be easily 
modulated by varying drug-loading concentration in the gelatin microbeads, 
the alginate-to-gelatin ratio, and temperature. 
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In addition, a dual-drug delivery system based on the chapter 3 was 
prepared and the release profiles of two drugs were investigated. The dual-
drug release test in vitro showed a fast release for FL loaded in alginate and 
a sustained release for RhB loaded in gelatin microbeads.  
Finally, an idea for the multi-drug delivery system was demonstrated by 
putting the rods of agarose gel and drug-loaded gelatin gel into a 
polycarbonate tube layer by layer. With the increase of the length of agarose 
gel or decrease of the temperature, release profiles of all the drugs could be 
declined. Multiple drugs could be loaded in different layers of gelatin gel. 
6.2    Future Work 
In this thesis, the model drugs we used are kind of dyes, not real drugs, it 
is better to transfer the drug delivery system to the practical application by 
using the real drugs. As for the fifth chapter, the suitable dimension and 
materials of the device also should be considered to improve. 
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